September 2, 2022 01:28 PM EDT
Pharma
Marketing

Mer­ck spells out ac­cess, en­vi­ron­men­tal goals in lat­est ESG re­port

Nicole DeFeudis

Editor

Ac­cess is a key theme in Mer­ck’s lat­est en­vi­ron­men­tal, so­cial and gov­er­nance (ESG) progress re­port, as the phar­ma gi­ant touts a deal to pro­vide more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Break­ing: J&J looks at po­ten­tial bid for In­tra-Cel­lu­lar — re­port

Ex­clu­sive: Buck­ing gene edit­ing down­turn, Tune rais­es $175M to bring epi­ge­net­ic edit­ing to clin­ic

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

Post-Hoc: Big Phar­ma is los­ing the AI tal­ent war

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

Post-Hoc: The em­bryo edit­ing de­bate is back

A service from the Financial Times